Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C, Kourtis G, Rucco AS, Nico A, Albanesi M, Giliberti L, D'Elia L, Caiaffa MF, Macchia L.
Di Bona D, et al. Among authors: albanesi m.
Respir Med. 2017 Sep;130:55-60. doi: 10.1016/j.rmed.2017.07.013. Epub 2017 Jul 19.
Respir Med. 2017.
PMID: 29206634
Free article.